Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy
- PMID: 32940104
- DOI: 10.1080/13816810.2020.1814344
Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy
Abstract
Background: Autosomal Dominant Optic Atrophy (ADOA) is caused by mutations in the Optic Atrophy 1 Gene which disrupts the OPA1 protein. This disruption affects the normal function of the protein; impairs fusion of the mitochondrial inner membrane; and prevents normal OPA1 protein degradation. These events cause damage in retinal ganglion cells that could affect the patients with symptoms ranging from none to legally blind.
Materials and methods: Our study identifies a missense variant mutation, c.1024 A > G (p.K342E), in OPA1 gene causing ADOA. Diagnosed clinically in three family members and the presence of this mutation was confirmed in two members by genetic testing. Pathogenic variants in OPA1 impact the secondary protein structure and function by causing non-conservative amino acid substitutions. We also modeled this mutation and compared it to the wild type using statistical mechanics.
Results and conclusions: The proband's pathogenic variant, c.1024 A > G (p.K342E), is located in the GTPase domain of OPA1 and causes changes in the protein structure by affecting the oligomerization pattern thus resulting in ADOA. Identifying the pathogenic potential of the missense mutations in the OPA1 gene using neoteric protein modeling techniques would help in the early detection of ADOA in patients who have family history of blindness. This action would help in providing early follow up, possible treatment in the future, and genetic counseling. Abbreviations: ADOA: Autosomal Dominant Optic Atrophy; CYCS: Caspase Activator Cytochrome C; OPA1: Optic Atrophy Gene 1; RGC: Retinal Ganglion Cells; VUS: Variant of Uncertain Significance.
Keywords: Autosomal Dominant Optic Atrophy (ADOA); Optic Atrophy Gene 1 (OPA1); gene mutation; molecular Genetics; novel mutation; pathogenicity; protein informatics; variant of uncertain significance.
Similar articles
-
Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene.J Neurol Sci. 2015 Apr 15;351(1-2):99-108. doi: 10.1016/j.jns.2015.02.047. Epub 2015 Mar 6. J Neurol Sci. 2015. PMID: 25796301
-
Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the OPA1 Gene.Int J Mol Sci. 2024 Jun 30;25(13):7240. doi: 10.3390/ijms25137240. Int J Mol Sci. 2024. PMID: 39000346 Free PMC article.
-
OPA1 mutations in dominant optic atrophy: domain-specific defects in mitochondrial fusion and apoptotic regulation.J Transl Med. 2025 Apr 24;23(1):471. doi: 10.1186/s12967-025-06471-w. J Transl Med. 2025. PMID: 40275276 Free PMC article.
-
Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.Mitochondrion. 2019 May;46:262-269. doi: 10.1016/j.mito.2018.07.006. Epub 2018 Aug 27. Mitochondrion. 2019. PMID: 30165240
-
OPA1-associated disorders: phenotypes and pathophysiology.Int J Biochem Cell Biol. 2009 Oct;41(10):1855-65. doi: 10.1016/j.biocel.2009.04.012. Epub 2009 Apr 21. Int J Biochem Cell Biol. 2009. PMID: 19389487 Review.
Cited by
-
Phenotypic screening models for rapid diagnosis of genetic variants and discovery of personalized therapeutics.Mol Aspects Med. 2023 Jun;91:101153. doi: 10.1016/j.mam.2022.101153. Epub 2022 Nov 18. Mol Aspects Med. 2023. PMID: 36411139 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous